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treatment regimens was evaluated by the standardized in-
terview. RESULTS: The QL tests revealed significantly
(Mann-Whitney) worse QL scores on all GSC and GWB
subscales in the investigated Belarusian female EH compared
with male ones (Gastral Complaints, Pains, Cardiac Com-
plaints, Exhaustion, Anxiety, Depression, Well-Being, Self-
Control, General Health, Vitality) with the total GSC In-
dex (mean  SD) 35.9  17.2 vs. 21.1  13.5 points (P 
0.001), and the total GWB index 76.2  15.7 vs. 87.9 
17.7 points (P  0.001), respectively. The total GSC and
GWB indexes were significantly (P  0.05) worse in the
EH treated on regular basis (14.5% of males and 38.5%
of females) compared with EH who did not treat their
known hypertension. QL scores did not correlate (Spear-
man) with age, body mass index, office blood pressure,
and duration of hypertension. In males, but not in fe-
males there was an association (ANOVA) of the total
GSC index with alcohol and coffee consumption (stan-
dardized interview), while abstinents had the lowest
scores (P  0.05). The high QL score, smoking, drinking
and male gender were revealed as factors of poor C.
CONCLUSIONS: Gender influences on the QL profile in
EH living in Belarus, and relates to their C, possibly via
certain life-style factors, this requiring gender-based deci-
sion-making for hypertension management improvement.
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OBJECTIVES: To investigate incremental cost-effective-
ness ratio (ICER) of some hypotensive drugs in elderly
patients with mild and moderate arterial hypertension.
METHODS: Analyses were based on patient data gath-
ered between January 1997 and August 1999 (n  210;
middle age 66,8  0,63). All these patients were divided
into seven groups. Six groups were treated monotherapy
by the following drugs: carvedilol, doxazosin, nifedipine-
GITS, enalapril maleat, indapamid, diltiazem. But the pa-
tients of the 7th group were not treated systematically by
various reasons. The received results were compared with
7th group. Supplementary effectiveness consisted of days
of successful treatment (DST). DST were included the
days where patient did not apply to in-patient, out-patient
and emergency care and also was not on dynamic obser-
vation and house hospital. RESULTS: ICER for patient
treated by nifedipine-GITS was $2,76 (95%; CI 0,7–
4,82). The number of DST was 78,27 (95%; CI 69,71–
86,83) per year. The indapamid group ($0,54) (95%;
CI (0,15)(0,93)) and 55,35 DST (95%; CI 51,07–
59,63). In enalapril group ($0,79) (95%; CI
(0,22)(1,36)) and 58,38 DST (95%; CI 48,93–67,83).
In diltiazem group ($1,6) (95%; CI (0,76)(2,44))
and 49,43 DST (95%; CI 43,25–55,61). In doxazosin
group $23,6 (95%; CI 11,52–35,68) and 37,62 DST
(95%; CI 31,5–43,74). In carvedilol group $3,0 (95%;
CI 1,74–4,26) and 71,42 DST (95%; CI 60,4–82,44).
CONCLUSION: ICER was compared expenditures and
effectiveness. It was revealed that using carvedilol and
nifedipine-GITS the patients had maximum of supple-
mentary successful days but it was required supplemen-
tary expenditures. Using indapamid, enalapril and dilt-
iazem the patients had less successful days but it was
economy, the expenditures were reduced. Using dox-
azosin the patients had few successful days and it was re-
quired considerable expenditures.
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OBJECTIVE: To model and predict hospitalization costs
after first acute coronary syndrome (ACS) based on age,
sex, social class, previous hospitalization for diabetes,
COAD and renal diseases. METHODS: The Cramer-
Lundberg insurance model was adapted to predict the
hospitalization costs within a given period. Three impor-
tant factors, costs per hospitalization, time to next hospi-
talization and time to death were modeled. The costs
were modeled by a gamma regression model using the
GEE approach to accommodate intra-patient correlation.
Parametric survival models were used for easy prediction.
Weibull regression was used for the recurrence of hospi-
talizations. Future costs can be predicted by combining
the models and using simulation. RESULTS: Average
costs increase with patient’s age. Compared with patients
over 80, the costs per hospital admission of those under
40 was only 44%. Previous hospitalization for diabetes,
COAD and renal diseases increases the costs by 25%,
12% and 12% respectively. Younger patients were more
likely to have a further hospitalization. The log-RR for
those under 40 is 0.36 (95% CI  0.24, 0.48) compared
with those over 80. On average, each previous ACS in-
creases the log-risk by 0.27 (95% CI  0.23, 0.31). Pre-
vious hospital admission for diabetes and renal diseases
also indicated higher risk with log-risk 0.34 (95% CI 
0.21, 0.47) and 0.53 (95%CI  0.28, 0.77) respectively.
Younger patients had lower mortality with log-RR for
those under 40 is 2.78 (95%CI  3.05, 2.50), com-
pared with those aged over 80. Previous hospital admis-
sions for diabetes, COAD and renal disease also indi-
cated higher mortality with log-RR 0.22 (95%CI  0.08,
0.36), 0.38 (95%CI  0.27, 0.49) and 0.86 (95%CI 
0.68, 1.03) respectively. CONCLUSION: The combined
model procedure provided a flexible approach to analyze
and predict hospitalization costs. Some factors may affect
the costs in several ways. This approach explored the role
of the factors in predicting individual costs.
